Headlines about Ardelyx (NASDAQ:ARDX) have trended positive this week, AlphaOne Sentiment reports. The research group, a subsidiary of Accern, identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. AlphaOne ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Ardelyx earned a news impact score of 0.27 on AlphaOne’s scale. AlphaOne also assigned news headlines about the biopharmaceutical company an impact score of 12 out of 100, indicating that recent media coverage is very unlikely to have an effect on the company’s share price in the near term.
These are some of the news headlines that may have impacted AlphaOne’s scoring:
- Ardelyx Inc (ARDX) Earns “Overweight” Rating from Cantor Fitzgerald (americanbankingnews.com)
- Ardelyx Inc (ARDX) Faces Heat for Tenapanor and Gets Price Target Chop (smarteranalyst.com)
- Ardelyx Inc (ARDX) Given “Buy” Rating at Citigroup Inc (americanbankingnews.com)
- Short Interest in Ardelyx Inc (ARDX) Decreases By 10.7% (americanbankingnews.com)
- AZN’s PACIFIC Proves To Have Depth, ARDX Abuzz, No Flashy Data From ALLSTAR (nasdaq.com)
Several research firms have recently issued reports on ARDX. Cantor Fitzgerald reiterated an “overweight” rating and issued a $12.00 target price (down previously from $19.00) on shares of Ardelyx in a research note on Friday. Zacks Investment Research lowered shares of Ardelyx from a “hold” rating to a “sell” rating in a research note on Tuesday, April 25th. Citigroup Inc reiterated a “buy” rating and issued a $12.00 target price (down previously from $17.00) on shares of Ardelyx in a research note on Monday. Finally, Wedbush reiterated an “outperform” rating and issued a $24.00 target price on shares of Ardelyx in a research note on Wednesday, February 15th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $16.40.
Ardelyx (NASDAQ:ARDX) traded down 4.297% during trading on Friday, reaching $6.125. 162,403 shares of the company traded hands. Ardelyx has a 52 week low of $6.10 and a 52 week high of $16.30. The firm’s market capitalization is $290.24 million. The company’s 50-day moving average price is $11.82 and its 200 day moving average price is $13.25.
Ardelyx (NASDAQ:ARDX) last posted its quarterly earnings results on Friday, May 5th. The biopharmaceutical company reported ($0.59) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.65) by $0.06. On average, equities research analysts expect that Ardelyx will post ($2.46) EPS for the current year.
TRADEMARK VIOLATION NOTICE: “Ardelyx (ARDX) Getting Positive News Coverage, Study Finds” was first reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark law. The legal version of this piece of content can be viewed at https://sportsperspectives.com/2017/05/19/ardelyx-ardx-getting-positive-news-coverage-study-finds.html.
Ardelyx Company Profile
Ardelyx, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutics focuses on addressing cardiorenal and gastrointestinal (GI) diseases. It operates through the research, development and commercialization of biopharmaceutical products segment. The Company’s products line includes cardiorenal portfolio and gastrointestinal portfolio.
Receive News & Ratings for Ardelyx Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardelyx Inc and related companies with MarketBeat.com's FREE daily email newsletter.